Literature DB >> 8100536

Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: differential effects of host conditioning with gamma radiation and cytotoxic drugs.

J D Down1, R E Ploemacher.   

Abstract

Transplant of sorted donor (B6-Gpi-1a) hematopoietic stem cell subsets and host (B6-Gpi-1b) treatment with total body irradiation (TBI) or cytotoxic drugs were compared for induction of short- and long-term engraftment in a murine chimera model of congenic bone marrow transplantation (BMT). Parallel studies on donor and host marrow were performed in vitro in long-term bone marrow cultures to determine early and late cobblestone area forming cell (CAFC) frequencies in the grafts or in the transplant recipients 1 day after conditioning. Bone marrow cells (BMC) sorted for high wheat germ agglutinin affinity (WGA ) were enriched about 30-fold for early developing CAFC (colony-forming unit-spleen [CFU-S]) but not for primitive late CAFC (pre-CFU-S). This fraction showed only temporary engraftment when transplanted in irradiated recipients. In contrast, the low affinity (WGA+) fraction were preferentially enriched (200- to 300-fold) for late developing CAFC and were very effective for providing stable long-term engraftment following transplantation. Substituting radiation for chemotherapy in the host conditioning treatment also had diverse effects on the development of bone marrow engraftment. Pretreatment with 5-fluorouracil (5-FU, 200 mg/kg) allowed a discrete wave of donor engraftment that peaked at 2 to 4 weeks and then subsided to leave mostly host cells at 10 weeks and beyond. Busulfan preparation gave over 50% engraftment at 1 month after BMT but this continued to increase to reach stable donor chimerism of 80 to 90% beyond 10 weeks. The level of long-term engraftment given by 50 mg/kg busulfan appeared similar to that induced by doses of 6 to 8 Gy TBI. The changing patterns of erythroid chimerism for each preparative agent showed a remarkable correlation with depletion of defined hematopoietic stem cell subsets as quantified using the CAFC assay at 1 day after recipient treatment. These findings collectively show that the level of depletion of host CFU-S (CAFC-10) determines the extent of early and transient repopulation, whereas the degree of pre-CFU-S (CAFC-35) depletion determines the percentage of stable chimerism. Preliminary data on bone marrow CAFC content at 9 months after busulfan and BMT revealed a long-term reduction of the stem cell pool by about 50% but with relatively minor effects on supporting bone marrow stromas. The differential cytotoxic effects on stem cell subsets in relation to subsequent donor marrow engraftment offer a systematic and mechanistic approach toward identifying more effective chemotherapeutic compounds for use in clinical BMT conditioning regimens.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100536

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  20 in total

1.  Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities.

Authors:  Jennifer E Adair; Xin Zhao; Sylvia Chien; Min Fang; Martin E Wohlfahrt; Grant D Trobridge; Jason A Taylor; Brian C Beard; Hans-Peter Kiem; Pamela S Becker
Journal:  J Mol Med (Berl)       Date:  2012-06-03       Impact factor: 4.599

2.  Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia.

Authors:  Kalindi Parmar; Peter Mauch; Jo-Anne Vergilio; Robert Sackstein; Julian D Down
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-20       Impact factor: 11.205

3.  Tolerization of a type I allergic immune response through transplantation of genetically modified hematopoietic stem cells.

Authors:  Ulrike Baranyi; Birgit Linhart; Nina Pilat; Martina Gattringer; Jessamyn Bagley; Ferdinand Muehlbacher; John Iacomini; Rudolf Valenta; Thomas Wekerle
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

4.  Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer.

Authors:  Gustavo Mostoslavsky; Attila J Fabian; Sean Rooney; Frederick W Alt; Richard C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-24       Impact factor: 11.205

5.  Human B cell development and antibody production in humanized NOD/SCID/IL-2Rγ(null) (NSG) mice conditioned by busulfan.

Authors:  Bongkum Choi; Eunyoung Chun; Miyoung Kim; Seong-Tae Kim; Keejung Yoon; Ki-Young Lee; Sung Joo Kim
Journal:  J Clin Immunol       Date:  2010-10-28       Impact factor: 8.317

6.  In vivo imaging of transplanted hematopoietic stem and progenitor cells in mouse calvarium bone marrow.

Authors:  Cristina Lo Celso; Charles P Lin; David T Scadden
Journal:  Nat Protoc       Date:  2010-12-09       Impact factor: 13.491

7.  Distribution of lentiviral vector integration sites in mice following therapeutic gene transfer to treat β-thalassemia.

Authors:  Keshet Ronen; Olivier Negre; Shannah Roth; Charlotte Colomb; Nirav Malani; Maria Denaro; Troy Brady; Floriane Fusil; Beatrix Gillet-Legrand; Kathleen Hehir; Yves Beuzard; Philippe Leboulch; Julian D Down; Emmanuel Payen; Frederic D Bushman
Journal:  Mol Ther       Date:  2011-03-08       Impact factor: 11.454

8.  Busulfan produces efficient human cell engraftment in NOD/LtSz-Scid IL2Rgamma(null) mice.

Authors:  Jun Hayakawa; Matthew M Hsieh; Naoya Uchida; Oswald Phang; John F Tisdale
Journal:  Stem Cells       Date:  2009-01       Impact factor: 6.277

9.  A novel competitive repopulation strategy to quantitate engraftment of ex vivo manipulated murine marrow cells in submyeloablated hosts.

Authors:  Brandon K Wyss; Justin L Meyers; Anthony L Sinn; Shanbao Cai; Karen E Pollok; W Scott Goebel
Journal:  Exp Hematol       Date:  2008-02-04       Impact factor: 3.084

10.  Oral Administration of Ren-Shen-Yang-Rong-Tang 'Ninjin'yoeito' Protects Against Hematotoxicity and Induces Immature Erythroid Progenitor Cells in 5-Fluorouracil-induced Anemia.

Authors:  Fumihide Takano; Yasuyuki Ohta; Tomoaki Tanaka; Kenroh Sasaki; Kyoko Kobayashi; Tomoya Takahashi; Nobuo Yahagi; Fumihiko Yoshizaki; Shinji Fushiya; Tomihisa Ohta
Journal:  Evid Based Complement Alternat Med       Date:  2007-10-27       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.